NCT02069639

TARC After alloSCT in Hodgkin's Lymphoma

Serum Thymus and Activation-regulated Chemokine (TARC) Level Monitoring May Predict Disease Relapse Detected by PET Scan After Reduced Intensity Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 22 (actual)
• Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Relapsed and refractory Hodgkin's lymphoma (HL) patients may experience long-term survival after allogeneic transplant (alloSCT), but disease recurrence represents the main cause of treatment failure. PET (positron-emission tomography) -positive patients after alloSCT have a dismal outcome. Serum TARC (thymus and activation-regulated chemokine) is produced by Reed-Sternberg cells and may be a marker of disease. Our study was aimed at assessing whether TARC levels after alloSCT were correlated to disease status and whether TARC monitoring could increase the ability to predict relapse.

Conditions

• Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation

Interventions

Type	Name	Description
OTHER	no treatment

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2014-02-24
• Last updated: 2014-02-24

Locations

1 site across 1 country: Italy